LYPD5

Across TCGA pan-cancer cohorts, LYPD5 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LYPD5 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LYPD5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LYPD5 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

HNSC and GBM are the cancer types where LYPD5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.879	0.640	.011	8	view →
GBM	DFS	Tertile	All	1.000	0.394	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

LYPD5–HNSC (DFS)

Open the HNSC breakdown →